Bank of New York Mellon Corp grew its holdings in Qiagen N.V. (NASDAQ:QGEN) by 1.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,289,162 shares of the company’s stock after buying an additional 22,587 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.57% of Qiagen worth $40,608,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Acrospire Investment Management LLC lifted its holdings in Qiagen by 11.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock worth $112,000 after buying an additional 349 shares during the period. Oppenheimer Asset Management Inc. lifted its holdings in Qiagen by 0.5% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 3,961 shares of the company’s stock worth $133,000 after buying an additional 20 shares during the period. Quadrant Capital Group LLC lifted its holdings in Qiagen by 4.1% in the 2nd quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock worth $183,000 after buying an additional 225 shares during the period. Koch Industries Inc. purchased a new stake in Qiagen in the 2nd quarter worth approximately $231,000. Finally, Public Employees Retirement Association of Colorado lifted its holdings in Qiagen by 3.5% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 7,214 shares of the company’s stock worth $242,000 after buying an additional 246 shares during the period. Institutional investors and hedge funds own 62.37% of the company’s stock.
Several equities research analysts have weighed in on the company. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Qiagen in a report on Tuesday, November 7th. Cowen restated a “hold” rating and issued a $33.00 target price on shares of Qiagen in a research note on Monday, August 14th. Zacks Investment Research cut Qiagen from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Commerzbank restated a “buy” rating on shares of Qiagen in a research note on Thursday, August 17th. Finally, TheStreet upgraded Qiagen from a “c+” rating to a “b+” rating in a research note on Tuesday, November 7th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the stock. Qiagen has a consensus rating of “Hold” and an average target price of $34.06.
Qiagen N.V. (NASDAQ QGEN) opened at $30.84 on Thursday. The company has a market capitalization of $7,062.02, a P/E ratio of 25.22, a PEG ratio of 1.90 and a beta of 1.10. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.33 and a quick ratio of 4.78. Qiagen N.V. has a one year low of $27.51 and a one year high of $36.34.
Qiagen (NASDAQ:QGEN) last released its earnings results on Monday, November 6th. The company reported $0.32 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.32. The company had revenue of $364.00 million during the quarter, compared to analysts’ expectations of $363.42 million. Qiagen had a return on equity of 11.36% and a net margin of 6.40%. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.29 EPS. analysts expect that Qiagen N.V. will post 1.25 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.thelincolnianonline.com/2017/12/07/qiagen-n-v-qgen-shares-bought-by-bank-of-new-york-mellon-corp.html.
Qiagen Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NASDAQ:QGEN).
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.